Shire presents data on ADHD treatment Intuniv

Shire has presented data from a new clinical study which demonstrates the efficacy of Intuniv as a treatment for attention deficit hyperactivity disorder (ADHD).

The nine-week phase study was conducted among 455 patients aged between six and 17 years of age and aimed to gauge the effectiveness of the drug when co-administered with stimulant medication.

It was found that patients using Intuniv were able to achieve a lower level of ADHD activity than those in the placebo control group, thereby meeting the study’s primary endpoint.

Based on these results, the company will look to continue its efforts to gain regulatory approval for the drug to be used as an adjunctive treatment with long-acting oral stimulants.

Michael Yasick, senior vice-president of Shire’s ADHD business unit, said: “Shire is committed to ADHD and continues to develop a range of ADHD treatments for health care providers and patients.”

Earlier this month, the company published its financial report for the first quarter of 2010, during which sales of core products increased by 36 per cent year-on-year.